Wei-Sheng Huang - JoVE Visualize

Showing results (41-50 of 42) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 42 results.

Journal of Medicinal Chemistry|June 2, 2010

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.

Bioorganic & Medicinal Chemistry Letters|November 24, 2022

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancerWei-Sheng Huang, Feng Li, Yongjin Gong, et al.

Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 42 results.

Journal of Medicinal Chemistry|June 2, 2010

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutantWei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, et al.

Bioorganic & Medicinal Chemistry Letters|November 24, 2022

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancerWei-Sheng Huang, Feng Li, Yongjin Gong, et al.

Pageof 5